NCT02882113 is a Phase 4 clinical trial of Advagraf in Liver Dysfunction, sponsored by Seoul National University Hospital.

Who is sponsoring NCT02882113?

NCT02882113 is sponsored by Seoul National University Hospital.

What drugs are being tested in NCT02882113?

Interventions in NCT02882113: Advagraf.

What condition does NCT02882113 study?

NCT02882113 studies Liver Dysfunction.

Is NCT02882113 still recruiting?

NCT02882113 is currently status unknown. Last updated 30 August 2016.

Last reviewed 2016-08-30 · How we verify

NCT02882113

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Influence of CYP3A5 Polymorphism on Liver Function Abnormality and the Trough Level Change After Conversion From Tacrolimus (Bid) to Advagraf® (qd) in Stable Liver Transplant Recipients

Status unknown Phase 4 Last updated 30 August 2016

What this trial tests

Phase 4 trial testing Advagraf in Liver Dysfunction in 60 participants. Status unknown.

Timeline

1 July 2016

Primary endpoint
1 August 2018

1 December 2018

Quick facts

Lead sponsor	Seoul National University Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 July 2016
Primary completion	1 August 2018
Estimated completion	1 December 2018
Sites	1 location across South Korea

Drugs / interventions tested

Advagraf — full drug profile →

Conditions studied

Liver Dysfunction — all drugs for Liver Dysfunction →

Sponsor

Seoul National University Hospital

Who can join

19 and older, any sex, with Liver Dysfunction. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

liver function abnormality rate
Time frame: 24 Weeks

Sponsor's own description

This study is a multicenter, single-arm, open-label, 24 weeks, and investigator-initiated clinical trial to assess the influence of CYP3A5 polymorphism on liver function abnormality and the trough level change after conversion to Advagraf® in liver transplant recipients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of <i>CYP3A5</i> on the Once-Daily Tacrolimus Conversion in Stable Liver Transplant Patients.
Kim JM, Ryu JH, Lee KW, Hong SK, et al · · 2020 · cited 5× · PMID 32911703 · DOI 10.3390/jcm9092897

Verify or expand the search:

Other trials of Advagraf

Trials testing the same drug.

NCT03603548 — Comparison of Safety and Efficacy of Two Variants of Prolonged - Released Tacrolimus (Advagraf vs. Envarsus ) in Patient · NA · unknown
NCT03216447 — A Study of Patient Adherence and Convenience to Immunosuppressive Agents in Newly Liver Transplant · Phase 4 · unknown
NCT02251691 — Influence of Once-daily Versus Twice-daily Immunosuppressant on Renal Transplant · Phase 4 · unknown
NCT02034747 — A Study to Assess the Efficacy and Safety of Advagraf® Switching From Cyclosporine Between the Group That Was Treated Wi · Phase 4 · completed
NCT02268201 — A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus · Phase 4 · terminated

Other recruiting trials for Liver Dysfunction

Currently open trials in the same condition.

NCT06173947 — SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury · recruiting
NCT06532214 — Clinical Retrospective Study Analysis of Postoperative Complications Following Hepatectomy · recruiting
NCT05793203 — Single-center Prospective Study of Non-invasive Methods for the Diagnosis of Postoperative Complications in Liver Transp · recruiting
NCT03519074 — Cisplatin Combined with Oral TS-1 in Patients with Advanced Solid Tumors with Different Degrees of Liver Dysfunction · Phase 2 · active not recruiting

Other Seoul National University Hospital trials

Trials by the same sponsor.

NCT07262944 — EOI Block in Otoplasty With Rib Cartilage Graft · NA · recruiting
NCT07464210 — Nemtabrutinib, Bortezomib, and Rituximab for WM · Phase 2 · not yet recruiting
NCT07550803 — Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery · NA · not yet recruiting
NCT07522138 — Home-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study · NA · not yet recruiting
NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02882113 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Seoul National University Hospital
Last refreshed: 30 August 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02882113.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing